Evoke Pharma (EVOK)
(Real Time Quote from BATS)
$4.75 USD
+0.24 (5.32%)
Updated Sep 23, 2024 11:46 AM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Evoke Pharma, Inc. [EVOK]
Reports for Purchase
Showing records 1 - 20 ( 79 total )
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
Gimoti - A Sea Change in Treatment of Diabetic Gastroparesis
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
3Q20 Financial Results; Gimoti Launch Advances; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
Gimoti Commercial Launch Initiated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
Chief Commercial Officer Appointed; Gimoti Launch in 4Q20; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
Launch Preparations Ongoing; 2Q20 Financials Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
Gimoti Commercial Manufacturing Initiated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
Gimoti Wins Hard-Fought Approval; Upgrading to Buy and $10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
Gimoti Trade Name Conditional Acceptance; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
1Q20 Financials Reported; Gimoti Decision Next Month; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
2019 Financials Reported; Gimoti Approval Decision Imminent; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
Gimoti Application Gets FDA Acceptance; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
Gimoti Resubmission Imminent; 3Q19 Financials; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
2Q19 Financial Results Reported; Gimoti Resubmission in 4Q19; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
Type A Meeting Request Submitted; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
1Q19 Financial Results Reported; Still Awaiting Regulatory Clarity; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
Complete Response Letter Received, as Expected; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
FDA Letter Raises Approvability Concerns; Stepping to the Sidelines Ahead of Approval Decision; Downgrading to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
Gimoti Approaches Moment of Truth; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R